Related references
Note: Only part of the references are listed.A Multicenter Evaluation of Ceftolozane/Tazobactam Treatment Outcomes in Immunocompromised Patients With Multidrug-Resistant Pseudomonas aeruginosa Infections
Delaney E. Hart et al.
OPEN FORUM INFECTIOUS DISEASES (2021)
Changing epidemiology of catheter-related bloodstream infections in neutropenic oncohematological patients
Dajana Lendak et al.
PLOS ONE (2021)
Multidrug-resistant, gram-negative infections in high-risk haematologic patients: an update on epidemiology, diagnosis and treatment
Carolina Garcia-Vidal et al.
CURRENT OPINION IN INFECTIOUS DISEASES (2021)
Inappropriate Empirical Antibiotic Treatment in High-risk Neutropenic Patients With Bacteremia in the Era of Multidrug Resistance
Gemma Martinez-Nadal et al.
CLINICAL INFECTIOUS DISEASES (2020)
Cefepime neurotoxicity: thresholds and risk factors. A retrospective cohort study
L. Boschung-Pasquier et al.
CLINICAL MICROBIOLOGY AND INFECTION (2020)
A Randomized, Double-Blind, Placebo-Controlled Trial (TAURCAT Study) of Citrate Lock Solution for Prevention of Endoluminal Central Venous Catheter Infection in Neutropenic Hematological Patients
Carlota Gudiol et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2020)
Real-World Experience with Ceftolozane-Tazobactam for Multidrug-Resistant Gram-Negative Bacterial Infections
Sarah C. J. Jorgensen et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2020)
Clinical characteristics of peripheral venous catheter-associated gram-negative bloodstream infection among patients with malignancy
Toshiharu Sasaki et al.
PLOS ONE (2020)
Mechanisms of high-level ceftolozane/tazobactam resistance in Pseudomonas aeruginosa from a severely neutropenic patient and treatment success from synergy with tobramycin
Wonhee So et al.
JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY (2019)
Ceftolozane-tazobactam versus meropenem for treatment of nosocomial pneumonia (ASPECT-NP): a randomised, controlled, double-blind, phase 3, non-inferiority trial
Marin H. Kollef et al.
LANCET INFECTIOUS DISEASES (2019)
A Case-Control Study of Real-Life Experience with Ceftolozane-Tazobactam in Patients with Hematologic Malignancy and Pseudomonas aeruginosa Infection
Ana Fernandez-Cruz et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2019)
Mechanisms leading to in vivo ceftolozane/tazobactam resistance development during the treatment of infections caused by MDR Pseudomonas aeruginosa
Pablo A. Fraile-Ribot et al.
JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY (2018)
Ceftolozane-tazobactam therapy for multidrug-resistant Pseudomonas aeruginosa infections in patients with hematologic malignancies and hematopoietic-cell transplant recipients
Morgan Hakki et al.
INFECTION (2018)
Salvage Therapy with CeftolozaneTazobactam for Multidrug-Resistant Pseudomonas aeruginosa Infections
Juan Jose Caston et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2017)
Use of ceftolozane/tazobactam as salvage therapy for infections due to extensively drug-resistant Pseudomonas aeruginosa
Aurelien Dinh et al.
INTERNATIONAL JOURNAL OF ANTIMICROBIAL AGENTS (2017)
Emergence of Ceftolozane-Tazobactam-Resistant Pseudomonas aeruginosa during Treatment Is Mediated by a Single AmpC Structural Mutation
Shawn H. MacVane et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2017)
Pseudomonas aeruginosa bacteraemia in patients with hematologic malignancies: risk factors, treatment and outcome
Polydoros Tofas et al.
DIAGNOSTIC MICROBIOLOGY AND INFECTIOUS DISEASE (2017)
Ceftolozane-Tazobactam Activity against Pseudomonas aeruginosa Clinical Isolates from US Hospitals: Report from the PACTS Antimicrobial Surveillance Program, 2012 to 2015
Dee Shortridge et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2017)
Multicenter Evaluation of Ceftolozane/Tazobactam for Serious Infections Caused by Carbapenem-Resistant Pseudomonas aeruginosa
Jose M. Munita et al.
CLINICAL INFECTIOUS DISEASES (2017)
Ceftolozane-Tazobactam for the Treatment of Multidrug-Resistant Pseudomonas aeruginosa Infections: Clinical Effectiveness and Evolution of Resistance
Ghady Haidar et al.
CLINICAL INFECTIOUS DISEASES (2017)
Ceftazidime/Avibactam and Ceftolozane/Tazobactam: Second-generation β-Lactam/β-Lactamase Inhibitor Combinations
David van Duin et al.
CLINICAL INFECTIOUS DISEASES (2016)
The growing threat of multidrug-resistant Gram-negative infections in patients with hematologic malignancies
Thomas M. Baker et al.
LEUKEMIA & LYMPHOMA (2016)
Use of Ceftolozane/Tazobactam in the Treatment of Multidrug-resistant Pseudomonas aeruginosa Bloodstream Infection in a Pediatric Leukemia Patient
Samuel L. Aitken et al.
PEDIATRIC INFECTIOUS DISEASE JOURNAL (2016)
Clinical features, aetiology and outcome of bacteraemic pneumonia in neutropenic cancer patients
Carlota Gudiol et al.
RESPIROLOGY (2016)
Bloodstream infections in neutropenic cancer patients: A practical update
Giulia Gustinetti et al.
VIRULENCE (2016)
Ceftolozane-tazobactam: A new-generation cephalosporin
David Cluck et al.
AMERICAN JOURNAL OF HEALTH-SYSTEM PHARMACY (2015)
Ceftolozane/Tazobactam Therapy of Respiratory Infections due to Multidrug-Resistant Pseudomonas aeruginosa
Michael S. Gelfand et al.
CLINICAL INFECTIOUS DISEASES (2015)
Ceftolozane/Tazobactam Plus Metronidazole for Complicated Intra-abdominal Infections in an Era of Multidrug Resistance: Results From a Randomized, Double-Blind, Phase 3 Trial (ASPECT-cIAI)
Joseph Solomkin et al.
CLINICAL INFECTIOUS DISEASES (2015)
Ceftolozane-tazobactam compared with levofloxacin in the treatment of complicated urinary-tract infections, including pyelonephritis: a randomised, double-blind, phase 3 trial (ASPECT-cUTI)
Florian M. Wagenlehner et al.
LANCET (2015)
Aetiology and resistance in bacteraemias among adult and paediatric haematology and cancer patients
Malgorzata Mikulska et al.
JOURNAL OF INFECTION (2014)
Changing aetiology, clinical features, antimicrobial resistance, and outcomes of bloodstream infection in neutropenic cancer patients
C. Gudiol et al.
CLINICAL MICROBIOLOGY AND INFECTION (2013)
Multidrug-resistant, extensively drug-resistant and pandrug-resistant bacteria: an international expert proposal for interim standard definitions for acquired resistance
A. -P. Magiorakos et al.
CLINICAL MICROBIOLOGY AND INFECTION (2012)
Multidrug resistant Pseudomonas aeruginosa bloodstream infection in adult patients with hematologic malignancies
Enrico Maria Trecarichi et al.
HAEMATOLOGICA-THE HEMATOLOGY JOURNAL (2011)
Bacteraernia in febrile neutropenic cancer patients
J. Klastersky et al.
INTERNATIONAL JOURNAL OF ANTIMICROBIAL AGENTS (2007)
Share Paper
